Can I Take L-Theanine with Repatha (Evolocumab)?

How Repatha (Evolocumab) Works in the Body

Repatha (evolocumab) is a fully human monoclonal antibody that binds and inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a serine protease that degrades LDL receptors on hepatocytes. By blocking PCSK9, evolocumab allows LDL receptors to recycle to the cell surface, removing more LDL-C from circulation. The FDA approved evolocumab in August 2015 for adults with heterozygous or homozygous familial hypercholesterolemia and for patients with established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL lowering beyond statins [1].

Pharmacokinetic Profile

Because evolocumab is a large-protein biologic (molecular weight approximately 144 kDa), it is not absorbed orally and cannot be administered as a pill. After subcutaneous injection of the 140 mg every-2-weeks dose, peak serum concentrations occur at approximately 3 to 4 days, with a half-life of roughly 11 to 17 days [1].

Critically, evolocumab undergoes proteolytic catabolism, the same pathway the body uses to break down any dietary protein. It does not interact with cytochrome P450 (CYP) 1A2, 2C9, 2C19, 2D6, or 3A4 enzymes [1]. It also does not involve P-glycoprotein or organic anion transporting polypeptide (OATP) drug transporters. This metabolic profile is why the FDA label for Repatha lists no drug-drug interactions based on CYP inhibition or induction [1].

Clinical Efficacy Data

The FOURIER trial (N=27,564) demonstrated that evolocumab 140 mg every 2 weeks reduced LDL-C by a mean of 59% from baseline (from a median of 92 mg/dL to 30 mg/dL) and reduced the composite risk of major adverse cardiovascular events by 15% over a median follow-up of 2.2 years (hazard ratio 0.85; 95% CI 0.79 to 0.92; P<0.001) [2]. That LDL reduction is the reason physicians are reluctant to have anything interfere with this medication's consistent delivery and absorption.

What L-Theanine Does Pharmacologically

L-theanine (gamma-glutamylethylamide) is a non-proteinogenic amino acid found predominantly in the leaves of Camellia sinensis (green tea). At oral doses of 100 to 400 mg, it crosses the blood-brain barrier via the large neutral amino acid transporter and modulates glutamatergic, GABAergic, and dopaminergic neurotransmission [3].

Absorption and Metabolism

After ingestion, L-theanine is hydrolyzed in the small intestinal brush border by glutaminase into glutamate and ethylamine. Neither metabolite is a known CYP inhibitor or inducer at physiological concentrations [3]. A 2012 pharmacokinetic study by Ogasawara et al. Confirmed that oral L-theanine 200 mg reaches peak plasma concentration (Cmax) within 30 to 60 minutes with a half-life of approximately 1.2 hours in healthy volunteers [4]. The short half-life means L-theanine clears the system well before the next evolocumab injection window.

Primary Pharmacodynamic Effects

L-theanine at 100 to 200 mg produces dose-dependent increases in alpha-wave brain activity, an effect measured by electroencephalography in a randomized crossover study by Nobre et al. (N=16) published in Asia Pacific Journal of Clinical Nutrition [5]. The compound reduces subjective anxiety scores without causing sedation at these doses. At 200 mg combined with 160 mg caffeine, it attenuated caffeine-induced blood pressure elevations by roughly 8 mmHg systolic in a double-blind crossover study (N=24) [6].

Repatha does not affect brain neurotransmitter systems, blood pressure homeostasis, or adrenergic tone in any way that would overlap with L-theanine's mechanism. The two agents operate on entirely separate biological targets.

Pharmacokinetic Interaction Assessment

A pharmacokinetic interaction requires one agent to alter the absorption, distribution, metabolism, or excretion of the other. For evolocumab and L-theanine, none of the four vectors present a plausible mechanism.

Absorption

Evolocumab is injected subcutaneously. L-theanine is taken orally. The two routes never share a common absorption surface, so competitive inhibition at intestinal transporters is not applicable.

Metabolism

As noted in the evolocumab FDA prescribing information, the antibody undergoes proteolytic degradation to peptide fragments and individual amino acids [1]. L-theanine is similarly hydrolyzed to amino acids. Neither compound passes through CYP450 enzymes. There is no shared metabolic enzyme that either compound could inhibit to raise or lower the blood level of the other.

Distribution and Protein Binding

Evolocumab's volume of distribution is approximately 3.3 L, consistent with a large protein largely confined to plasma and interstitial fluid [1]. L-theanine is a small neutral amino acid with low plasma protein binding. No competitive displacement between the two is biologically plausible.

Excretion

Large monoclonal antibodies are not renally filtered in meaningful amounts; they are catabolized into amino acids that are then recycled or excreted normally. L-theanine metabolites are renally excreted. No shared renal transporter pathway exists between them.

Bottom line on pharmacokinetics: The interaction probability is negligible. The National Institutes of Health Office of Dietary Supplements notes that interaction risks are highest when supplements share metabolic enzymes (particularly CYP3A4) with the co-administered drug [7]. Neither evolocumab nor L-theanine meaningfully engages CYP3A4.

Pharmacodynamic Interaction Assessment

A pharmacodynamic interaction occurs when two agents produce additive, synergistic, or antagonistic effects on the same physiological endpoint, even if their metabolic pathways are separate.

Cardiovascular Parameters

Evolocumab's cardiovascular effects are confined to LDL-C lowering and, secondarily, reduction of ASCVD event rates. It does not acutely alter heart rate, blood pressure, or cardiac conduction. L-theanine at 200 mg has been reported to modestly attenuate caffeine-induced blood pressure rises but does not independently lower blood pressure in normotensive or hypertensive individuals [6]. No shared cardiovascular endpoint exists where the two compounds would conflict.

QTc Interval

Neither evolocumab nor L-theanine appears on the CredibleMeds/Arizona CERT list of QTc-prolonging agents. The FOURIER trial did not report QTc prolongation as an adverse event signal [2]. This is clinically relevant because some supplements (notably high-dose fish oil in certain formulations) can interact with cardiac electrophysiology. L-theanine does not.

Lipid Metabolism

L-theanine itself has no established direct effect on LDL-C, HDL-C, or triglycerides at conventional supplement doses. A 2016 systematic review of green tea extract (which contains L-theanine plus catechins) found a modest reduction in LDL-C of approximately 2.19 mg/dL vs. Placebo, though the authors attributed most of that effect to catechins rather than L-theanine specifically [8]. Taking isolated L-theanine without catechins is not expected to meaningfully alter lipid levels, and any minor additive LDL reduction would be beneficial rather than harmful for a patient already on Repatha.

Immune System

Evolocumab is a monoclonal antibody and carries a low but real risk of injection-site reactions and, rarely, hypersensitivity. L-theanine has anti-inflammatory properties in animal models, but human data are insufficient to conclude it would amplify or suppress any immune-mediated reaction to evolocumab. This remains a theoretical unknown rather than a documented concern.

What the Interaction Databases Say

The three most commonly referenced supplement-drug interaction databases provide the following classifications for L-theanine with cardiovascular medications:

Natural Medicines (formerly Natural Standard): Rates the L-theanine-cardiovascular drug combination as having insufficient reliable evidence of interaction, with no mechanistic basis for concern identified for monoclonal antibody biologics specifically.

Drugs.com interaction checker: Returns no interaction record between L-theanine and evolocumab as of the most recent database update. The absence of a record reflects the lack of reported adverse events in the post-marketing pharmacovigilance data submitted to the FDA.

FDA Adverse Event Reporting System (FAERS): A search of the FAERS database for co-reported adverse events involving evolocumab and L-theanine yields no disproportionality signal in the published literature.

This three-database concordance is meaningful. The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol states, "Non-statin therapies... Should be considered in patients who are statin-intolerant or who require additional LDL-C lowering," and cautions physicians to review all concomitant supplements at each visit [9]. That guideline does not list L-theanine as a contraindicated or caution-class supplement for PCSK9 inhibitor users.

Practical Guidance for Patients Already Taking Both

Most patients reading this article are either already combining L-theanine with Repatha or actively considering it. Here is concrete guidance organized by situation.

If You Are New to L-Theanine and Already on Repatha

Start at the lowest studied dose, typically 100 to 200 mg per day of a standardized L-theanine supplement. There is no pharmacokinetic basis to require dose separation from your Repatha injection, but taking L-theanine in the morning and injecting Repatha in the evening is a simple and harmless habit that keeps any theoretical absorption window variables irrelevant.

Inform your cardiologist before starting. The conversation is brief. The 2022 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction recommends that clinicians actively ask about supplement use at every visit with patients on PCSK9 inhibitors [10].

If You Are Already Taking Both Without Incident

Continue your current regimen and report your supplement use at your next appointment. Bring the product label so your clinician can verify the actual L-theanine content (products vary widely, from 50 mg to 400 mg per serving). Your next scheduled lipid panel will confirm that LDL-C remains at goal (typically <55 mg/dL for very high-risk ASCVD patients per current ACC/AHA guidance [9]).

Monitoring Parameters

No additional laboratory monitoring is required specifically for the L-theanine/evolocumab combination. Standard monitoring for evolocumab includes:

• Fasting lipid panel at 4 to 12 weeks after initiation, then every 3 to 12 months [9]
• Liver function tests only if symptoms suggest hepatotoxicity (L-theanine is not hepatotoxic at standard doses)
• Blood pressure check at routine visits (L-theanine does not raise blood pressure)

When to Call Your Doctor

Contact your prescribing physician if you notice injection-site reactions worsening after starting L-theanine (though a causal link is implausible, reporting changes in symptom patterns is always appropriate), or if you experience new symptoms within days of adding any supplement. That is standard clinical practice, not a concern specific to this combination.

Special Populations

Patients with Familial Hypercholesterolemia (FH)

Patients with heterozygous FH (HeFH) have a 1-in-250 prevalence in the general population, per data from the FH Foundation and confirmed in the CASCADE FH registry [11]. These patients often take multiple lipid-lowering agents simultaneously. L-theanine's anxiolytic properties may be appealing to FH patients who experience anxiety related to their cardiovascular diagnosis or statin side effects. The pharmacological rationale for safety in this group is the same as in the general population.

Elderly Patients

Older adults may metabolize L-theanine more slowly due to reduced intestinal brush-border enzyme activity, but this does not create an interaction with evolocumab. Evolocumab's pharmacokinetics are not significantly altered by age, as confirmed in the subgroup analyses of FOURIER [2].

Patients on Concurrent Statins

Many evolocumab patients also take high-intensity statins such as atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg. Statins are CYP3A4 (atorvastatin) or BCRP transporter (rosuvastatin) substrates. L-theanine does not meaningfully inhibit CYP3A4 or BCRP at doses up to 400 mg, based on in vitro data reviewed in a 2020 analysis of green tea constituents [8]. The three-drug combination (statin plus evolocumab plus L-theanine) does not appear to carry additive interaction risk beyond the individual pairwise assessments.

The Quality Problem: Choosing a Reputable L-Theanine Product

Supplement quality varies dramatically. A 2023 ConsumerLab analysis found that approximately 30% of randomly selected amino acid supplements did not meet their labeled potency claims. For patients on Repatha who are managing serious cardiovascular disease, accuracy of dosing matters. Look for L-theanine products that carry NSF International, USP Verified, or Informed Sport certification. These seals confirm third-party testing for label accuracy and absence of adulterants.

Suntheanine is the most studied branded form of L-theanine, used in the majority of the published human randomized controlled trials cited in this article. If a product does not specify the form, contact the manufacturer directly before purchasing.

Summary of Evidence Quality

The evidence supporting the safety of this combination is built on three pillars. First, mechanistic reasoning from well-established pharmacokinetic data on both compounds individually is strong. Second, absence of reported interactions in post-marketing surveillance (FAERS) and interaction databases is reassuring, though absence of evidence is not evidence of absence. Third, the short duration of clinical trial data on this specific combination (no head-to-head RCT has directly studied evolocumab plus L-theanine) means the evidence quality for the combination specifically is rated as "insufficient but reassuring" rather than "proven safe" in the formal hierarchy of evidence.

Patients and clinicians should calibrate their expectations accordingly. The interaction is not expected to occur, and there is no mechanism by which it plausibly would, but this is not the same as a completed phase III safety trial confirming zero risk.